Skip to main navigation

The link is opening in a new window or tab that may or may not accessible Opens an external site Opens an external site in a new window

Pre-Header Contact

800-449-3353 | custserv@rockwellmed.com |

Footer Socials

Pre-Header Menu

Careers | Contact Us

Client Header Links

Home
Our Company
Our Therapeutic Focus
- Iron Deficiency Anemia
- Anemia in Renal Disease
Our Technology
Hemodialysis Concentrates
Investors

Investor Relations

Press Releases

Main navigation

Investor Home
Press Releases
Events & Presentations
Corporate Governance
Management
Annual Meeting
Financial Information
Stock Information
Investor FAQs
Contact Us
Shareholder Tools

Press Releases

Year

Aug 10, 2020

Rockwell Medical, Inc. Provides Second Quarter 2020 Financial and Operational Update

PDF Version

Aug 03, 2020

Rockwell Medical to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

PDF Version

Jun 10, 2020

Rockwell Medical, Inc. Appoints Dr. Allen R. Nissenson to Board of Directors

PDF Version

May 26, 2020

Rockwell Medical, Inc. Files New Drug Submission with Health Canada for Marketing Approval of Triferic® AVNU™

PDF Version

May 11, 2020

Rockwell Medical, Inc. Provides First Quarter 2020 Financial and Operational Update and Top-line Real-World Triferic Data

PDF Version

Apr 20, 2020

Rockwell Medical, Inc. Appoints Russell H. Ellison, M.D., M.Sc., as President and Chief Executive Officer

PDF Version

Mar 31, 2020

Rockwell Medical, Inc. Appoints Pharmaceutical Industry Leader Robert S. Radie to Board of Directors

PDF Version

Mar 27, 2020

Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients

PDF Version

Mar 20, 2020

Rockwell Medical, Inc. Confirms Medical Resource Acquisition Group’s Director Nominations Are Invalid

PDF Version

Mar 17, 2020

Rockwell Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Shareholder Tools

Snapshot

Email Alerts

RSS News Feeds

Have any questions?

Phone 248 432-1997

invest@rockwellmed.com

Client Header Links

Home
Our Company
Our Therapeutic Focus
Our Technology
Hemodialysis Concentrates
Investors
Contact

Footer Socials